Northwell Health’s Feinstein Institutes for Medical Research has received $850,000 from the National Institutes of Health (NIH) to advance a non-invasive diagnostic test for endometriosis using menstrual blood. This funding will support the ROSE II clinical trial, aiming to reduce diagnostic delays—currently averaging years—for the estimated 10% of women and adolescents who suffer from this chronic condition.
Endometriosis, a condition where tissue similar to the uterine lining grows outside the uterus, profoundly impacts quality of life, often causing debilitating pain and infertility. Current diagnosis relies heavily on laparoscopic surgery, an invasive procedure with inherent risks and costs. The promise of a simple, accurate blood test represents a paradigm shift in endometriosis care, potentially enabling earlier intervention and improved patient outcomes. This NIH investment underscores the growing recognition of endometriosis as a significant public health concern demanding innovative diagnostic solutions.
In Plain English: The Clinical Takeaway
- Faster Diagnosis: This research aims to create a test using menstrual blood that could diagnose endometriosis without the need for surgery.
- Reduced Suffering: Earlier diagnosis means women can start treatment sooner, potentially alleviating years of pain and improving their chances of successful fertility treatment.
- Empowering Patients: A reliable test validates patient experiences and can help overcome the frustrating delays and dismissals many women face when seeking care.
The Biological Basis of the ROSE Study: Biomarkers in Menstrual Effluent
The Research OutSmarts Endometriosis (ROSE) study, initiated in 2013, is predicated on the understanding that menstrual flow isn’t simply shed uterine lining. it contains a wealth of biological information. Researchers hypothesize that women with endometriosis exhibit distinct molecular signatures within their menstrual effluent – the fluid discharged during menstruation – reflecting altered cellular activity and inflammatory processes associated with the disease. Specifically, the team is focusing on identifying epigenetic markers, modifications to DNA that don’t change the genetic code itself but can alter gene expression. These epigenetic changes, potentially influenced by the ectopic endometrial tissue, could serve as reliable biomarkers for diagnosis. The underlying mechanism of action involves analyzing RNA molecules within the menstrual blood to identify patterns unique to endometriosis. This approach leverages advances in genomics and molecular diagnostics to move beyond subjective symptom assessment towards objective, quantifiable data.
Funding Transparency and the RADx Tech Program
The $850,000 in funding originates from the NIH’s Rapid Acceleration of Diagnostics Technology (RADx Tech) program. RADx Tech was established in response to the COVID-19 pandemic to accelerate the development and commercialization of innovative diagnostic technologies. Although initially focused on infectious diseases, the program’s scope has expanded to address other critical diagnostic gaps, including those in women’s health. The funding is structured as a prize, awarded to the Feinstein Institutes team based on achieving specific milestones in the ROSE II clinical trial. This prize-based model incentivizes rapid innovation and efficient resource allocation. It’s important to note that Northwell Innovations also provided a $1 million award in 2018, demonstrating a sustained commitment to this research. The NIH funding is a direct federal investment, and the RADx Tech program is overseen by the National Institute of Biomedical Imaging and Bioengineering (NIBIB).
ROSE II: A Prospective, Multi-Center Clinical Trial
The ROSE II clinical trial, launched in 2022, represents a crucial step towards validating the menstrual blood test. Here’s a prospective, multi-center study recruiting women aged 18-40 who suspect they have endometriosis and are scheduled for diagnostic laparoscopy. Participants collect menstrual blood samples at home using a simple, non-invasive kit. These samples are then analyzed by the Feinstein Institutes team, and the results are compared to the definitive diagnosis established during surgery. The primary endpoint of the trial is diagnostic accuracy, measured by sensitivity (the ability to correctly identify women *with* endometriosis) and specificity (the ability to correctly identify women *without* endometriosis). A key aspect of the trial design is its focus on a diverse patient population, aiming to ensure the test performs reliably across different ethnicities and demographic groups. The trial is currently enrolling participants, and preliminary results are anticipated in late 2026 or early 2027.
| Trial Phase | Participants (N) | Primary Endpoint | Key Biomarkers Investigated |
|---|---|---|---|
| ROSE Study (Phase I) | >3700 | Biomarker Discovery | Epigenetic markers, RNA expression profiles |
| ROSE II (Phase II/III) | Ongoing Recruitment | Diagnostic Accuracy (Sensitivity & Specificity) | Validated biomarker panel from Phase I |
Geographical Impact and Regulatory Pathways
The potential impact of this diagnostic test extends far beyond Northwell Health’s network. If successful, the test could grow widely available through commercial laboratories, significantly improving access to endometriosis diagnosis across the United States and internationally. The ultimate goal is FDA approval, which would require demonstrating robust clinical validity and analytical performance. The FDA’s review process for diagnostic tests involves rigorous scrutiny of clinical trial data, manufacturing processes, and quality control measures. In Europe, the test would need to meet the requirements of the European Medicines Agency (EMA) and obtain CE marking to be marketed within the European Union. The NHS in the United Kingdom is actively exploring the adoption of innovative diagnostic technologies to improve patient care, and a non-invasive endometriosis test would likely be of significant interest.
“The current diagnostic pathway for endometriosis is often a long and frustrating journey for patients. A simple blood test could revolutionize care by enabling earlier diagnosis, reducing unnecessary surgeries, and improving quality of life for millions of women.” – Dr. Ronald DePinho, President and CEO of the MD Anderson Cancer Center, commenting on the broader implications of non-invasive diagnostic technologies in women’s health.
Contraindications & When to Consult a Doctor
While a menstrual blood test for endometriosis is anticipated to be a safe and non-invasive procedure, it’s crucial to understand its limitations. This test is *not* a substitute for a comprehensive medical evaluation. Women experiencing symptoms suggestive of endometriosis – such as pelvic pain, heavy bleeding, and infertility – should consult with a gynecologist for a thorough assessment. The test is intended for women who are actively menstruating; it is not appropriate for postmenopausal women or those who have undergone hysterectomy. A negative test result does not definitively rule out endometriosis, as the condition can be heterogeneous and biomarker levels may vary. Any persistent or worsening symptoms should prompt further investigation, potentially including laparoscopic surgery.
The development of a non-invasive diagnostic test for endometriosis represents a significant advancement in women’s health. The NIH’s investment in the ROSE study and ROSE II clinical trial underscores the importance of addressing this often-overlooked condition. While regulatory hurdles remain, the potential benefits – faster diagnosis, reduced suffering, and improved patient outcomes – are substantial. Continued research and clinical validation will be essential to translate this promising technology into routine clinical practice.
References
- National Institutes of Health. (2023). RADx Tech Program. https://www.nibib.nih.gov/research-topics/radx-tech
- Bulun, S. E. (2009). Endometriosis. New England Journal of Medicine, 360(3), 268–279. https://doi.org/10.1056/NEJMra0803889
- Giudice, L. C., & Kao, L. C. (2004). Endometriosis. The Lancet, 364(9447), 1789–1799. https://doi.org/10.1016/S0140-6736(04)69325-8
- World Health Organization. (2023). Endometriosis. https://www.who.int/news-room/fact-sheets/detail/endometriosis
